English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAxicabtagene ciloleucel, commonly known as axi-cel, is an innovative immunotherapy that uses modified T cells to target and destroy cancer cells. Approved for patients who have not responded to at least two prior lines of therapy, axicabtagene ciloleucel has been a game-changer in treating large B-cell lymphoma.
Tag: CAR T cell
St. Jude scientists create more efficient CAR immunotherapies using a molecular anchor
St. Jude scientists added a small physical structure called an anchor domain to the CAR molecule. The anchor domain connects the CAR to the internal infrastructure of the immune cell. It augments and helps organize the immune synapse
Penn Medicine and Children’s Hospital of Philadelphia to Host Symposium on the Future of Cell and Gene Therapies
Penn Medicine and Children’s Hospital of Philadelphia (CHOP) will host a virtual event on May 6 and 7 that will bring together cell and gene therapy leaders from the two institutions and around the world to discuss the latest achievements in the field, novel strategies, and future developments and applications for chimeric antigen receptor, CAR, T cell therapy and more.
Moffitt Researchers Use Mathematical Modeling to Analyze Dynamics of CAR T-Cell Therapy
In an article published in Proceedings of the Royal Society B, Moffitt Cancer Center researchers use mathematical modeling to help explain why CAR T cells work in some patients and not in others.
Moffitt Researchers Identify Why CAR T Therapy May Fail in Some Lymphoma Patients
In a new study published in Blood, the official journal of the American Society of Hematology, Moffitt researchers show that immune dysregulation can directly affect the efficacy of CAR T therapy in patients with diffuse large B-cell lymphoma.
Moffitt Researchers Create Chimeric Antigen Receptor Mutations to Enhance CAR T Cell Activity and Survival
Moffitt Cancer Center researchers are working to improve CAR T responses and make those responses more long-lasting for patients. In a new article published in Cancer Immunology Research, the team shares its findings, which show alterations to a specific domain of the chimeric antigen receptor enhances CAR T-cell activity and survival.
UCLA receives nearly $14 million from NIH to investigate gene therapy to combat HIV
UCLA researchers and colleagues have received a $13.65 million grant from the National Institutes of Health to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV.